This textbook serves as a comprehensive reference on the latest science underlying the development of biological therapies, as well as their use in animal and human studies of rheumatological disease. Part A covers targets of emerging therapies - targeting/manipulating cells, targeting cell surface receptors, targeting cytokines, inflammatory mediators and transcription factors, and targeting plasma molecules. Part B then examines the use and implementation of these new therapies in the clinic, covering their use in treating specific rheumatological conditions. Part C discusses issues relating to study design and regulatory issues in the US and Europe.
'…the immense value of this book lies in its ability to convey a target-directed approach to management of the rheumatic diseases. It is this type of perspective that represents the future of practice in the field of immune-mediated diseases and in medicine in general.' - Doody Publishing Review
'…this book is superior to the general textbooks in both the depth of information provided on the subject of targeted therapies and the range of relevant topics that are discussed.' - American College of Physicians
Part A. Targets. Section I: Targeting/Manipulating Cells. T-cells. B-cells. Macrophages. Dendritic cells. Neutrophils. Fibroblasts. Mast Cells. Section II: Targeting Cell Surface Receptors. Complement Receptors. Fc-Receptors. CD-28. Fas. Section III: Targeting Cytokines. TNF-alpha. IL-1. IL-6. IL-18. IL-12. IL-15. Th1/Th2 balance a) Experimental models of rheumatological diseases b) Human disease. OPG. Chemokines. The balance between pro- and anti- inflammatory cytokines. Section IV. Targeting Inflammatory Mediators and Transcription Factors. iNOS. COX/PG synthases. Matrix molecules. NFkB. Jak/STATs. MMPs. Angiogenesis. Section V: Targeting. Immunoglobulins. Complement. Apheresis. Part B. Studies in Human and Experimental Rheumatic Diseases. Ethical Issues. Rheumatoid Arthritis. Biologics in Early Arthritis. Juvenile Arthritis. Psoriatic arthritis/psoriasis. Spondylarthritis. Systemic Lupus Erythematosus. Vasculitis. Myositis. Part C. Study Design. Randomized Controlled Trials. Long-Term Observational Studies. Long-Term Monitoring of Experimental (Novel) Therapies. Community-Based Studies. Regulatory Issues - FDA Index. Section II: Targeting Cell Surface Receptors. Section III: Targeting Cytokines. Section IV: Targeting Inflammatory mediators and Transcription Factors.